Fire side chat from the UBS Swiss Equity Technology and Innovation Days on 14 Nov 2023
Disclaimer and other important notes
Disclaimer and other important notes
Ad-hoc trading update
MEDMIX HALF-YEAR RESULTS 2023
Investor Presentation
Disclaimer / Safe harbor statement under the US private securities litigation reform act 1995
medmix Half-Year 2023 Results Webcast Replay_July 20 2023
Half-year results 2023
High-precision delivery
Solid underlying business momentum in H1 2023 restrained by transitory factors Strong performance expected in H2 2023 with mid-term outlook confirmed
Investor Presentation
Investor Presentation
medmix Annual Results 2022 webcast replay_February 22 2023
Annual Results 2022
High-precision delivery
Investor Presentation
Investor Presentation
High-precision delivery
Half year results 2022
medmix midyear results 2022 webcast replay_July 21 2022
The safe harbor statement under the US private securities litigation reform act 1995
High-precision delivery
Annual Results 2021
medmix annual results 2021 webcast replay_February 22 2022
Investor Presentation
Combined and carve-out interim financial statements 2021 and 2020